<?xml version="1.0" encoding="UTF-8" ?>
			<?xml-stylesheet href="/rss/rss2html.xsl" type="text/xsl" media="screen"?>
			<rss version="2.0" xmlns:alacra="http://www.alacra.com" xmlns:sdc="http://www.alacra.com/sdc" xmlns:ccbn="http://www.alacra.com/ccbn" ><channel><title>Ranbaxy Laboratories Ltd. RSS Research Feed - Subscribe Today - AlacraStore.com</title>
<description>Ranbaxy Laboratories Ltd.</description>
<link>http://www.alacrastore.com/company-snapshot/Ranbaxy_Laboratories_Ltd-1051166</link>
<lastBuildDate>24 Nov 2009 08:35:48 EST</lastBuildDate>
<alacra:xlsid>1051166</alacra:xlsid>
<alacra:company>Ranbaxy Laboratories Ltd.</alacra:company>
<language>en</language>
<generator>AlacraStore RSS Builder 1.0</generator>
<ttl>30</ttl>
<item><link>http://www.alacrastore.com/storecontent/ccbn/T2515699</link><ccbn:docid xmlns:ccbn="http://www.alacra.com/ccbn">T2515699</ccbn:docid><guid isPermaLink="false">ccbn/T2515699</guid><ccbn:index_mode xmlns:ccbn="http://www.alacra.com/ccbn">norm</ccbn:index_mode><pubDate>26 Oct 2009 02:06:00 EST</pubDate><ccbn:eventid xmlns:ccbn="http://www.alacra.com/ccbn">2515699</ccbn:eventid><ccbn:headline xmlns:ccbn="http://www.alacra.com/ccbn">Final Transcript of RANBAXY earnings conference call or presentation, 26-Oct-09 12:00pm IST</ccbn:headline><ccbn:name xmlns:ccbn="http://www.alacra.com/ccbn">RANBAXY LABORATORIES LTD</ccbn:name><ccbn:price xmlns:ccbn="http://www.alacra.com/ccbn">54.0000</ccbn:price><ccbn:revision xmlns:ccbn="http://www.alacra.com/ccbn">Final</ccbn:revision><ccbn:storetitle xmlns:ccbn="http://www.alacra.com/ccbn">RANBAXY LABORATORIES LTD Q3 2009 Earnings Conference Call Transcript</ccbn:storetitle><ccbn:ticker xmlns:ccbn="http://www.alacra.com/ccbn">RANBAXY</ccbn:ticker><ccbn:time xmlns:ccbn="http://www.alacra.com/ccbn">12:00pm IST</ccbn:time><title>RANBAXY LABORATORIES LTD Q3 2009 Earnings Conference Call Transcript</title><ccbn:type xmlns:ccbn="http://www.alacra.com/ccbn">Transcript</ccbn:type><description>...Sandeep Juneja Ranbaxy Laboratories Limited - Director, M&amp;A and IR Atul Sobti Ranbaxy Laboratories Limited - CEO and Managing Director Omesh Sethi Ranbaxy Laboratories Limited - CFO...

</description><category>Credit &amp; Investment Research</category><alacra:ip>Thomson StreetEvents</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/ccbn/T2344420</link><ccbn:docid xmlns:ccbn="http://www.alacra.com/ccbn">T2344420</ccbn:docid><guid isPermaLink="false">ccbn/T2344420</guid><ccbn:index_mode xmlns:ccbn="http://www.alacra.com/ccbn">norm</ccbn:index_mode><pubDate>24 Jul 2009 05:08:00 EST</pubDate><ccbn:eventid xmlns:ccbn="http://www.alacra.com/ccbn">2344420</ccbn:eventid><ccbn:headline xmlns:ccbn="http://www.alacra.com/ccbn">Final Transcript of RANBAXY earnings conference call or presentation, 24-Jul-09 6:15pm IST</ccbn:headline><ccbn:name xmlns:ccbn="http://www.alacra.com/ccbn">RANBAXY LABORATORIES LTD</ccbn:name><ccbn:price xmlns:ccbn="http://www.alacra.com/ccbn">54.0000</ccbn:price><ccbn:revision xmlns:ccbn="http://www.alacra.com/ccbn">Final</ccbn:revision><ccbn:storetitle xmlns:ccbn="http://www.alacra.com/ccbn">RANBAXY LABORATORIES LTD Q2 2009 Earnings Conference Call Transcript</ccbn:storetitle><ccbn:ticker xmlns:ccbn="http://www.alacra.com/ccbn">RANBAXY</ccbn:ticker><ccbn:time xmlns:ccbn="http://www.alacra.com/ccbn">6:15pm IST</ccbn:time><title>RANBAXY LABORATORIES LTD Q2 2009 Earnings Conference Call Transcript</title><ccbn:type xmlns:ccbn="http://www.alacra.com/ccbn">Transcript</ccbn:type><description>...Sandeep Juneja Ranbaxy Laboratories Limited - Director - M&amp;A and IR Atul Sobti Ranbaxy Laboratories Limited - CEO, Managing Director Omesh Sethi Ranbaxy Laboratories Limited - CFO C O N F E R E N C E C A L L P A R T I C I P A N T S...

</description><category>Credit &amp; Investment Research</category><alacra:ip>Thomson StreetEvents</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/ccbn/T2244110</link><ccbn:docid xmlns:ccbn="http://www.alacra.com/ccbn">T2244110</ccbn:docid><guid isPermaLink="false">ccbn/T2244110</guid><ccbn:index_mode xmlns:ccbn="http://www.alacra.com/ccbn">norm</ccbn:index_mode><pubDate>26 May 2009 11:06:00 EST</pubDate><ccbn:eventid xmlns:ccbn="http://www.alacra.com/ccbn">2244110</ccbn:eventid><ccbn:headline xmlns:ccbn="http://www.alacra.com/ccbn">Final Transcript of RANBAXY conference call or presentation, 25-May-09 6:15pm IST</ccbn:headline><ccbn:name xmlns:ccbn="http://www.alacra.com/ccbn">RANBAXY LABORATORIES LTD</ccbn:name><ccbn:price xmlns:ccbn="http://www.alacra.com/ccbn">54.0000</ccbn:price><ccbn:revision xmlns:ccbn="http://www.alacra.com/ccbn">Final</ccbn:revision><ccbn:storetitle xmlns:ccbn="http://www.alacra.com/ccbn">RANBAXY LABORATORIES LTD Management Briefing Conference Call Transcript</ccbn:storetitle><ccbn:ticker xmlns:ccbn="http://www.alacra.com/ccbn">RANBAXY</ccbn:ticker><ccbn:time xmlns:ccbn="http://www.alacra.com/ccbn">6:15pm IST</ccbn:time><title>RANBAXY LABORATORIES LTD Management Briefing Conference Call Transcript</title><ccbn:type xmlns:ccbn="http://www.alacra.com/ccbn">Transcript</ccbn:type><description>...Sandeep Juneja Ranbaxy Laboratories Ltd. - Director, M&amp;A and Investor Relations Tsutomu Une Ranbaxy Laboratories Ltd. - Chairman Atul Sobti Ranbaxy Laboratories Ltd. - CEO and MD Omesh Sethi Ranbaxy Laboratories Ltd. - CFO C O N F E R E N C E C A L L P A R T I C I P A N T S...

</description><category>Credit &amp; Investment Research</category><alacra:ip>Thomson StreetEvents</alacra:ip></item><item><title>Ranbaxy Laboratories Ltd acquires Ochoa Lab-Derma Prod Brands from Ochoa Laboratories Ltd</title><description>INDIA - Ranbaxy Laboratories Ltd acquired the dermatological and lifestyle product brands of Ochoa Laboratories Ltd, a manufacturer of pharmaceutical products.</description><pubDate>23 May 2009 10:27:06 EST</pubDate><sdc:company_cusip xmlns:sdc="http://www.alacra.com/sdc">751881</sdc:company_cusip><sdc:target_company_cusip xmlns:sdc="http://www.alacra.com/sdc">67529J</sdc:target_company_cusip><sdc:company_cusip_up xmlns:sdc="http://www.alacra.com/sdc">23186L</sdc:company_cusip_up><sdc:target_company_cusip_up xmlns:sdc="http://www.alacra.com/sdc">67526W</sdc:target_company_cusip_up><sdc:company xmlns:sdc="http://www.alacra.com/sdc">Ranbaxy Laboratories Ltd</sdc:company><sdc:target_company xmlns:sdc="http://www.alacra.com/sdc">Ochoa Laboratories Ltd- Dermatological &amp; Lifestyle Products Brands</sdc:target_company><sdc:company_up xmlns:sdc="http://www.alacra.com/sdc">Daiichi Sankyo Co Ltd</sdc:company_up><sdc:target_company_up xmlns:sdc="http://www.alacra.com/sdc">Ochoa Laboratories Ltd</sdc:target_company_up><link>http://www.alacrastore.com/storecontent/Thomson_M%26A/Ranbaxy_Laboratories_Ltd_acquires_Ochoa_Lab_Derma_Prod_Brands_from_Ochoa_Laboratories_Ltd-2075711040</link><guid isPermaLink="false">sdc/2075711040</guid><sdc:deal xmlns:sdc="http://www.alacra.com/sdc"><sdc:deal_no>2075711040</sdc:deal_no><sdc:_copyright><sdc:value>Copyright Â© 2009, Thomson Financial, All Rights Reserved</sdc:value></sdc:_copyright><sdc:a_EXCHANGE><sdc:value>Bombay</sdc:value></sdc:a_EXCHANGE><sdc:a_MAINDUSTRY><sdc:value>Drugs</sdc:value></sdc:a_MAINDUSTRY><sdc:a_NATION><sdc:value>India</sdc:value></sdc:a_NATION><sdc:a_SICDESC><sdc:value>Pharmaceutical preparations</sdc:value></sdc:a_SICDESC><sdc:a_SICPI><sdc:value>2834</sdc:value></sdc:a_SICPI><sdc:a_STATE><sdc:value>FF</sdc:value></sdc:a_STATE><sdc:a_STATELONG><sdc:value>Foreign</sdc:value></sdc:a_STATELONG><sdc:a_STATUS><sdc:value>Public</sdc:value></sdc:a_STATUS><sdc:a_TICKER><sdc:value>500359</sdc:value></sdc:a_TICKER><sdc:asic_SIC><sdc:value sdc:p="0">2833:Medicinal chemicals and botanical products</sdc:value><sdc:value sdc:p="1">2834:Pharmaceutical preparations</sdc:value><sdc:value sdc:p="2">2836:Biological products, except diagnostic substances</sdc:value></sdc:asic_SIC><sdc:aupsic_SIC><sdc:value sdc:p="0">2833:Medicinal chemicals and botanical products</sdc:value><sdc:value sdc:p="1">2834:Pharmaceutical preparations</sdc:value><sdc:value sdc:p="2">2879:Pesticides and agricultural chemicals, nec</sdc:value><sdc:value sdc:p="3">5122:Drugs, drug proprietaries, and druggists' sundries</sdc:value><sdc:value sdc:p="4">5191:Farm supplies</sdc:value></sdc:aupsic_SIC><sdc:b_MAINDUSTRY><sdc:value>Drugs</sdc:value></sdc:b_MAINDUSTRY><sdc:b_NATION><sdc:value>India</sdc:value></sdc:b_NATION><sdc:b_SICDESC><sdc:value>Pharmaceutical preparations</sdc:value></sdc:b_SICDESC><sdc:b_SICPI><sdc:value>2834</sdc:value></sdc:b_SICPI><sdc:b_STATE><sdc:value>FF</sdc:value></sdc:b_STATE><sdc:b_STATELONG><sdc:value>Foreign</sdc:value></sdc:b_STATELONG><sdc:b_STATUS><sdc:value>Subsidiary</sdc:value></sdc:b_STATUS><sdc:c_ACIDGEN><sdc:value>150047002</sdc:value></sdc:c_ACIDGEN><sdc:c2up_BUSS><sdc:value>Mnfr,whl pharm</sdc:value></sdc:c2up_BUSS><sdc:c3up_BUSS><sdc:value>Mnfr pharm</sdc:value></sdc:c3up_BUSS><sdc:co_DESCR><sdc:value>Unspecified</sdc:value></sdc:co_DESCR><sdc:cs_DESCR><sdc:value>Assets</sdc:value></sdc:cs_DESCR><sdc:d_TCIDGEN><sdc:value>1084408001</sdc:value></sdc:d_TCIDGEN><sdc:date_lastupdate><sdc:value>May 23 2009</sdc:value></sdc:date_lastupdate><sdc:finbltm_BV><sdc:value>0.00000</sdc:value></sdc:finbltm_BV><sdc:finbltm_CASH><sdc:value>0.00000</sdc:value></sdc:finbltm_CASH><sdc:finbltm_CASHFLOW><sdc:value>0.00000</sdc:value></sdc:finbltm_CASHFLOW><sdc:finbltm_CASHFLOW1><sdc:value>0.00000</sdc:value></sdc:finbltm_CASHFLOW1><sdc:finbltm_CASHFLOW2><sdc:value>0.00000</sdc:value></sdc:finbltm_CASHFLOW2><sdc:finbltm_CASHFLOW3><sdc:value>0.00000</sdc:value></sdc:finbltm_CASHFLOW3><sdc:finbltm_CASHFLOW4><sdc:value>0.00000</sdc:value></sdc:finbltm_CASHFLOW4><sdc:finbltm_CASHFLOW5><sdc:value>0.00000</sdc:value></sdc:finbltm_CASHFLOW5><sdc:finbltm_COMEQ><sdc:value>0.00000</sdc:value></sdc:finbltm_COMEQ><sdc:finbltm_DEBTRAT><sdc:value>0.00000</sdc:value></sdc:finbltm_DEBTRAT><sdc:finbltm_DSER2><sdc:value>0.00000</sdc:value></sdc:finbltm_DSER2><sdc:finbltm_EBIT><sdc:value>0.00000</sdc:value></sdc:finbltm_EBIT><sdc:finbltm_EPS><sdc:value>0.00000</sdc:value></sdc:finbltm_EPS><sdc:finbltm_NI><sdc:value>0.00000</sdc:value></sdc:finbltm_NI><sdc:finbltm_PTINC><sdc:value>0.00000</sdc:value></sdc:finbltm_PTINC><sdc:finbltm_SALES><sdc:value>0.00000</sdc:value></sdc:finbltm_SALES><sdc:finbltm_STDEBT><sdc:value>0.00000</sdc:value></sdc:finbltm_STDEBT><sdc:finbltm_TASS><sdc:value>0.00000</sdc:value></sdc:finbltm_TASS><sdc:fiscal_ADCR><sdc:value>0.00000</sdc:value></sdc:fiscal_ADCR><sdc:fiscal_ANI><sdc:value>0.00000</sdc:value></sdc:fiscal_ANI><sdc:fiscal_APFDCR><sdc:value>0.00000</sdc:value></sdc:fiscal_APFDCR><sdc:fiscal_ASALES><sdc:value>0.00000</sdc:value></sdc:fiscal_ASALES><sdc:fiscal_ATASS><sdc:value>0.00000</sdc:value></sdc:fiscal_ATASS><sdc:fiscal_RATE><sdc:value>0.00000</sdc:value></sdc:fiscal_RATE><sdc:g_SEQ><sdc:value sdc:p="0">1.00000</sdc:value><sdc:value sdc:p="1">2.00000</sdc:value><sdc:value sdc:p="2">3.00000</sdc:value><sdc:value sdc:p="3">4.00000</sdc:value><sdc:value sdc:p="4">5.00000</sdc:value><sdc:value sdc:p="5">6.00000</sdc:value><sdc:value sdc:p="6">7.00000</sdc:value><sdc:value sdc:p="7">8.00000</sdc:value><sdc:value sdc:p="8">9.00000</sdc:value><sdc:value sdc:p="9">10.00000</sdc:value><sdc:value sdc:p="10">11.00000</sdc:value><sdc:value sdc:p="11">12.00000</sdc:value><sdc:value sdc:p="12">13.00000</sdc:value><sdc:value sdc:p="13">14.00000</sdc:value><sdc:value sdc:p="14">15.00000</sdc:value><sdc:value sdc:p="15">16.00000</sdc:value><sdc:value sdc:p="16">17.00000</sdc:value><sdc:value sdc:p="17">18.00000</sdc:value><sdc:value sdc:p="18">19.00000</sdc:value><sdc:value sdc:p="19">20.00000</sdc:value><sdc:value sdc:p="20">21.00000</sdc:value><sdc:value sdc:p="21">22.00000</sdc:value><sdc:value sdc:p="22">23.00000</sdc:value><sdc:value sdc:p="23">24.00000</sdc:value><sdc:value sdc:p="24">25.00000</sdc:value><sdc:value sdc:p="25">26.00000</sdc:value><sdc:value sdc:p="26">27.00000</sdc:value><sdc:value sdc:p="27">28.00000</sdc:value><sdc:value sdc:p="28">29.00000</sdc:value><sdc:value sdc:p="29">30.00000</sdc:value><sdc:value sdc:p="30">31.00000</sdc:value></sdc:g_SEQ><sdc:g_TEST><sdc:value sdc:p="0">Ranbaxy Laboratories Ltd,</sdc:value><sdc:value sdc:p="1">located in Gurgaon, India,</sdc:value><sdc:value sdc:p="2">manufactures pharmaceutical</sdc:value><sdc:value sdc:p="3">products. The company engages</sdc:value><sdc:value sdc:p="4">in the production, marketing,</sdc:value><sdc:value sdc:p="5">and distribution of dosage</sdc:value><sdc:value sdc:p="6">forms and active</sdc:value><sdc:value sdc:p="7">pharmaceutical ingredients</sdc:value><sdc:value sdc:p="8">(API). It offers formulations,</sdc:value><sdc:value sdc:p="9">API and intermediates,</sdc:value><sdc:value sdc:p="10">generics, drug discovery, and</sdc:value><sdc:value sdc:p="11">consumer health care products.</sdc:value><sdc:value sdc:p="12">The company's products include</sdc:value><sdc:value sdc:p="13">inter alia, Simvastatin,</sdc:value><sdc:value sdc:p="14">CoAmoxyclav, Amoxycillin,</sdc:value><sdc:value sdc:p="15">Ciprofloxacin, Isotretinon,</sdc:value><sdc:value sdc:p="16">and Cephalexin. Ranbaxy</sdc:value><sdc:value sdc:p="17">Laboratories also offers</sdc:value><sdc:value sdc:p="18">chyawanprash under Chyawan</sdc:value><sdc:value sdc:p="19">Active brand name. It offers</sdc:value><sdc:value sdc:p="20">products in the areas of</sdc:value><sdc:value sdc:p="21">anti-infective, oncology,</sdc:value><sdc:value sdc:p="22">cardiovascular, central</sdc:value><sdc:value sdc:p="23">nervous system, respiratory,</sdc:value><sdc:value sdc:p="24">dermatology, orthopedics,</sdc:value><sdc:value sdc:p="25">nutritional, and urology</sdc:value><sdc:value sdc:p="26">segments. The company markets</sdc:value><sdc:value sdc:p="27">its products in the US, India,</sdc:value><sdc:value sdc:p="28">Europe, Russia/CIS, Brazil,</sdc:value><sdc:value sdc:p="29">and South Africa. The company</sdc:value><sdc:value sdc:p="30">was founded in 1961.</sdc:value></sdc:g_TEST><sdc:g_business><sdc:value sdc:p="0">Ranbaxy Laboratories Ltd, located in Gurgaon, India,</sdc:value><sdc:value sdc:p="1">manufactures pharmaceutical products. The company engages in</sdc:value><sdc:value sdc:p="2">the production, marketing, and distribution of dosage forms</sdc:value><sdc:value sdc:p="3">and active pharmaceutical ingredients (API). It offers</sdc:value><sdc:value sdc:p="4">formulations, API and intermediates, generics, drug</sdc:value><sdc:value sdc:p="5">discovery, and consumer health care products. The company's</sdc:value><sdc:value sdc:p="6">products include inter alia, Simvastatin, CoAmoxyclav,</sdc:value><sdc:value sdc:p="7">Amoxycillin, Ciprofloxacin, Isotretinon, and Cephalexin.</sdc:value><sdc:value sdc:p="8">Ranbaxy Laboratories also offers chyawanprash under Chyawan</sdc:value><sdc:value sdc:p="9">Active brand name. It offers products in the areas of</sdc:value><sdc:value sdc:p="10">anti-infective, oncology, cardiovascular, central nervous</sdc:value><sdc:value sdc:p="11">system, respiratory, dermatology, orthopedics, nutritional,</sdc:value><sdc:value sdc:p="12">and urology segments. The company markets its products in</sdc:value><sdc:value sdc:p="13">the US, India, Europe, Russia/CIS, Brazil, and South Africa.</sdc:value><sdc:value sdc:p="14">The company was founded in 1961.</sdc:value></sdc:g_business><sdc:g_business1><sdc:value>Ranbaxy Laboratories Ltd, located in Gurgaon, India, manufactures pharmaceutical products. The company engages in the production, marketing, and distribution of dosage forms and active pharmaceutical ingredients (API). It offers formulations, API and intermediates, generics, drug discovery, and consumer health care products. The company's products include inter alia, Simvastatin, CoAmoxyclav, Amoxycillin, Ciprofloxacin, Isotretinon, and Cephalexin. Ranbaxy Laboratories also offers chyawanprash under Chyawan Active brand name. It offers products in the areas of anti-infective, oncology, cardiovascular, central nervous system, respiratory, dermatology, orthopedics, nutritional, and urology segments. The company markets its products in the US, India, Europe, Russia/CIS, Brazil, and South Africa. The company was founded in 1961.</sdc:value></sdc:g_business1><sdc:h_SEQ><sdc:value sdc:p="0">1.00000</sdc:value><sdc:value sdc:p="1">2.00000</sdc:value><sdc:value sdc:p="2">3.00000</sdc:value><sdc:value sdc:p="3">4.00000</sdc:value><sdc:value sdc:p="4">5.00000</sdc:value></sdc:h_SEQ><sdc:h_TEST><sdc:value sdc:p="0">Dermatological and lifestyle</sdc:value><sdc:value sdc:p="1">product brands owned by Ochoa</sdc:value><sdc:value sdc:p="2">Laboratories Ltd, located in</sdc:value><sdc:value sdc:p="3">India, manufactures</sdc:value><sdc:value sdc:p="4">pharmaceutical products.</sdc:value></sdc:h_TEST><sdc:h_business><sdc:value sdc:p="0">Dermatological and lifestyle product brands owned by Ochoa</sdc:value><sdc:value sdc:p="1">Laboratories Ltd, located in India, manufactures</sdc:value><sdc:value sdc:p="2">pharmaceutical products.</sdc:value></sdc:h_business><sdc:h_business1><sdc:value>Dermatological and lifestyle product brands owned by Ochoa Laboratories Ltd, located in India, manufactures pharmaceutical products.</sdc:value></sdc:h_business1><sdc:i_AFEEPCT><sdc:value>0.00000</sdc:value></sdc:i_AFEEPCT><sdc:i_AFEETOT><sdc:value>0.00000</sdc:value></sdc:i_AFEETOT><sdc:i_ATERMFEE><sdc:value>0.00000</sdc:value></sdc:i_ATERMFEE><sdc:i_COMOUT><sdc:value>0.00000</sdc:value></sdc:i_COMOUT><sdc:i_CROSS1><sdc:value>Y</sdc:value></sdc:i_CROSS1><sdc:i_DATEANN><sdc:value>21 May 09</sdc:value></sdc:i_DATEANN><sdc:i_DATEANN2><sdc:value>Thu, 21 May 2009 00:00:00 EST</sdc:value></sdc:i_DATEANN2><sdc:i_DATEANNS><sdc:value>Date Announced: 05/21/2009</sdc:value></sdc:i_DATEANNS><sdc:i_DATEEFF><sdc:value>21 May 09</sdc:value></sdc:i_DATEEFF><sdc:i_DATEEFFS><sdc:value>Date Effective: 05/21/2009</sdc:value></sdc:i_DATEEFFS><sdc:i_DATEUNCON><sdc:value>21 May 09</sdc:value></sdc:i_DATEUNCON><sdc:i_DESCR><sdc:value>Acq. of Assets</sdc:value></sdc:i_DESCR><sdc:i_DESCR1><sdc:value>Friendly</sdc:value></sdc:i_DESCR1><sdc:i_FEEPCT><sdc:value>0.00000</sdc:value></sdc:i_FEEPCT><sdc:i_FEETOT><sdc:value>0.00000</sdc:value></sdc:i_FEETOT><sdc:i_HOSTAFEETOT><sdc:value>0.00000</sdc:value></sdc:i_HOSTAFEETOT><sdc:i_HOSTENTVAL><sdc:value>0.00000</sdc:value></sdc:i_HOSTENTVAL><sdc:i_HOSTFEETOT><sdc:value>0.00000</sdc:value></sdc:i_HOSTFEETOT><sdc:i_HOSTPR><sdc:value>0.00000</sdc:value></sdc:i_HOSTPR><sdc:i_HOSTPRLABEL><sdc:value>Price/Share</sdc:value></sdc:i_HOSTPRLABEL><sdc:i_HOSTTFEETOT><sdc:value>0.00000</sdc:value></sdc:i_HOSTTFEETOT><sdc:i_HOSTVALUE><sdc:value>0</sdc:value></sdc:i_HOSTVALUE><sdc:i_HOSTVALUE1><sdc:value>0.00000</sdc:value></sdc:i_HOSTVALUE1><sdc:i_HOST_EQVAL><sdc:value>0.00000</sdc:value></sdc:i_HOST_EQVAL><sdc:i_HOST_RANKVAL><sdc:value>0</sdc:value></sdc:i_HOST_RANKVAL><sdc:i_HOST_RANKVAL1><sdc:value>0.00000</sdc:value></sdc:i_HOST_RANKVAL1><sdc:i_PCTACQ><sdc:value>100.00000</sdc:value></sdc:i_PCTACQ><sdc:i_PCTOWN><sdc:value>100.00000</sdc:value></sdc:i_PCTOWN><sdc:i_PR><sdc:value>0.00000</sdc:value></sdc:i_PR><sdc:i_PR_INITIAL><sdc:value>0.00000</sdc:value></sdc:i_PR_INITIAL><sdc:i_RANKVAL><sdc:value>0.00000</sdc:value></sdc:i_RANKVAL><sdc:i_RANK_HOSTRANKVAL><sdc:value>0</sdc:value></sdc:i_RANK_HOSTRANKVAL><sdc:i_RATE><sdc:value>0.00000</sdc:value></sdc:i_RATE><sdc:i_STATUS_MMC><sdc:value>N</sdc:value></sdc:i_STATUS_MMC><sdc:i_STGVAL><sdc:value>0.00000</sdc:value></sdc:i_STGVAL><sdc:i_TERMFEE><sdc:value>0.00000</sdc:value></sdc:i_TERMFEE><sdc:i_TFEEPCT><sdc:value>0.00000</sdc:value></sdc:i_TFEEPCT><sdc:i_TFEETOT><sdc:value>0.00000</sdc:value></sdc:i_TFEETOT><sdc:i_TTERMFEE><sdc:value>0.00000</sdc:value></sdc:i_TTERMFEE><sdc:i_VALLIA><sdc:value>0.00000</sdc:value></sdc:i_VALLIA><sdc:i_VALNOLIA><sdc:value>0.00000</sdc:value></sdc:i_VALNOLIA><sdc:i_VALUE><sdc:value>0.00000</sdc:value></sdc:i_VALUE><sdc:j_EQVALCF><sdc:value>0.00000</sdc:value></sdc:j_EQVALCF><sdc:j_EVCF><sdc:value>0.00000</sdc:value></sdc:j_EVCF><sdc:j_EVEBIT><sdc:value>0.00000</sdc:value></sdc:j_EVEBIT><sdc:j_EVNI><sdc:value>0.00000</sdc:value></sdc:j_EVNI><sdc:j_EVSALES><sdc:value>0.00000</sdc:value></sdc:j_EVSALES><sdc:j_MPE><sdc:value>0.00000</sdc:value></sdc:j_MPE><sdc:j_MPRICEBOOK><sdc:value>0.00000</sdc:value></sdc:j_MPRICEBOOK><sdc:j_PHELD><sdc:value>0.00000</sdc:value></sdc:j_PHELD><sdc:j_PSOUGHT><sdc:value>100.00000</sdc:value></sdc:j_PSOUGHT><sdc:j_RANKVALCF><sdc:value>0.00000</sdc:value></sdc:j_RANKVALCF><sdc:j_RANKVALEB><sdc:value>0.00000</sdc:value></sdc:j_RANKVALEB><sdc:j_RANKVALNA><sdc:value>0.00000</sdc:value></sdc:j_RANKVALNA><sdc:j_RANKVALNI><sdc:value>0.00000</sdc:value></sdc:j_RANKVALNI><sdc:j_RANKVALSALES><sdc:value>0.00000</sdc:value></sdc:j_RANKVALSALES><sdc:j_VALEB><sdc:value>0.00000</sdc:value></sdc:j_VALEB><sdc:j_VALNI><sdc:value>0.00000</sdc:value></sdc:j_VALNI><sdc:j_VALSALES><sdc:value>0.00000</sdc:value></sdc:j_VALSALES><sdc:m_AMV><sdc:value>0.00000</sdc:value></sdc:m_AMV><sdc:m_CF3YGR><sdc:value>0.00000</sdc:value></sdc:m_CF3YGR><sdc:m_CF5YGR><sdc:value>0.00000</sdc:value></sdc:m_CF5YGR><sdc:m_DCR><sdc:value>0.00000</sdc:value></sdc:m_DCR><sdc:m_ENTVAL><sdc:value>0.00000</sdc:value></sdc:m_ENTVAL><sdc:m_EPS3YGR><sdc:value>0.00000</sdc:value></sdc:m_EPS3YGR><sdc:m_EPS5YGR><sdc:value>0.00000</sdc:value></sdc:m_EPS5YGR><sdc:m_LTD><sdc:value>0.00000</sdc:value></sdc:m_LTD><sdc:m_MV><sdc:value>0.00000</sdc:value></sdc:m_MV><sdc:m_NETASS><sdc:value>0.00000</sdc:value></sdc:m_NETASS><sdc:m_NETASS3YGR><sdc:value>0.00000</sdc:value></sdc:m_NETASS3YGR><sdc:m_NETASS5YGR><sdc:value>0.00000</sdc:value></sdc:m_NETASS5YGR><sdc:m_NI3YGR><sdc:value>0.00000</sdc:value></sdc:m_NI3YGR><sdc:m_NI5YGR><sdc:value>0.00000</sdc:value></sdc:m_NI5YGR><sdc:n_SEQ><sdc:value sdc:p="0">1.00000</sdc:value><sdc:value sdc:p="1">2.00000</sdc:value><sdc:value sdc:p="2">3.00000</sdc:value><sdc:value sdc:p="3">4.00000</sdc:value><sdc:value sdc:p="4">5.00000</sdc:value><sdc:value sdc:p="5">6.00000</sdc:value><sdc:value sdc:p="6">7.00000</sdc:value></sdc:n_SEQ><sdc:n_SYNOPSIS><sdc:value sdc:p="0">INDIA - Ranbaxy Laboratories</sdc:value><sdc:value sdc:p="1">Ltd acquired the</sdc:value><sdc:value sdc:p="2">dermatological and lifestyle</sdc:value><sdc:value sdc:p="3">product brands of Ochoa</sdc:value><sdc:value sdc:p="4">Laboratories Ltd, a</sdc:value><sdc:value sdc:p="5">manufacturer of</sdc:value><sdc:value sdc:p="6">pharmaceutical products.</sdc:value></sdc:n_SYNOPSIS><sdc:n_synopsis2><sdc:value>INDIA - Ranbaxy Laboratories Ltd acquired the dermatological and lifestyle product brands of Ochoa Laboratories Ltd, a manufacturer of pharmaceutical products.</sdc:value></sdc:n_synopsis2><sdc:n_synopsis3><sdc:value sdc:p="0">INDIA - Ranbaxy Laboratories Ltd acquired the dermatological and lifestyle product brands</sdc:value><sdc:value sdc:p="1">of Ochoa Laboratories Ltd, a manufacturer of pharmaceutical products.</sdc:value></sdc:n_synopsis3><sdc:n_synopsis4><sdc:value>INDIA - Ranbaxy Laboratories Ltd acquired the dermatological and lifestyle product brands of Ochoa Laboratories Ltd, a manufacturer of pharmaceutical products.</sdc:value></sdc:n_synopsis4><sdc:n_synopsis5><sdc:value sdc:p="0">INDIA - Ranbaxy Laboratories Ltd acquired the dermatological and lifestyle product brands of Ochoa Laboratories Ltd, a manufacturer of</sdc:value><sdc:value sdc:p="1">pharmaceutical products.</sdc:value></sdc:n_synopsis5><sdc:q_DESCR><sdc:value>Completed</sdc:value></sdc:q_DESCR><sdc:q_HOSTANETASS><sdc:value>0.00000</sdc:value></sdc:q_HOSTANETASS><sdc:q_HOSTANILTM><sdc:value>0.00000</sdc:value></sdc:q_HOSTANILTM><sdc:q_HOSTASALESLTM><sdc:value>0.00000</sdc:value></sdc:q_HOSTASALESLTM><sdc:q_HOSTATASS><sdc:value>0.00000</sdc:value></sdc:q_HOSTATASS><sdc:q_HOSTBOOKVALUE><sdc:value>0.00000</sdc:value></sdc:q_HOSTBOOKVALUE><sdc:q_HOSTCASHFLOW><sdc:value>0.00000</sdc:value></sdc:q_HOSTCASHFLOW><sdc:q_HOSTCASHFLOW1><sdc:value>0.00000</sdc:value></sdc:q_HOSTCASHFLOW1><sdc:q_HOSTCASHFLOW2><sdc:value>0.00000</sdc:value></sdc:q_HOSTCASHFLOW2><sdc:q_HOSTCASHFLOW3><sdc:value>0.00000</sdc:value></sdc:q_HOSTCASHFLOW3><sdc:q_HOSTCASHFLOW4><sdc:value>0.00000</sdc:value></sdc:q_HOSTCASHFLOW4><sdc:q_HOSTCASHFLOW5><sdc:value>0.00000</sdc:value></sdc:q_HOSTCASHFLOW5><sdc:q_HOSTCOMMONEQUITY><sdc:value>0.00000</sdc:value></sdc:q_HOSTCOMMONEQUITY><sdc:q_HOSTEBITLTM><sdc:value>0.00000</sdc:value></sdc:q_HOSTEBITLTM><sdc:q_HOSTEPS1><sdc:value>0.00000</sdc:value></sdc:q_HOSTEPS1><sdc:q_HOSTEPS2><sdc:value>0.00000</sdc:value></sdc:q_HOSTEPS2><sdc:q_HOSTEPS3><sdc:value>0.00000</sdc:value></sdc:q_HOSTEPS3><sdc:q_HOSTEPS4><sdc:value>0.00000</sdc:value></sdc:q_HOSTEPS4><sdc:q_HOSTEPS5><sdc:value>0.00000</sdc:value></sdc:q_HOSTEPS5><sdc:q_HOSTEPSLTM><sdc:value>0.00000</sdc:value></sdc:q_HOSTEPSLTM><sdc:q_HOSTNETASS><sdc:value>0.00000</sdc:value></sdc:q_HOSTNETASS><sdc:q_HOSTNETASS1><sdc:value>0.00000</sdc:value></sdc:q_HOSTNETASS1><sdc:q_HOSTNETASS2><sdc:value>0.00000</sdc:value></sdc:q_HOSTNETASS2><sdc:q_HOSTNETASS3><sdc:value>0.00000</sdc:value></sdc:q_HOSTNETASS3><sdc:q_HOSTNETASS4><sdc:value>0.00000</sdc:value></sdc:q_HOSTNETASS4><sdc:q_HOSTNETASS5><sdc:value>0.00000</sdc:value></sdc:q_HOSTNETASS5><sdc:q_HOSTNI1><sdc:value>0.00000</sdc:value></sdc:q_HOSTNI1><sdc:q_HOSTNI2><sdc:value>0.00000</sdc:value></sdc:q_HOSTNI2><sdc:q_HOSTNI3><sdc:value>0.00000</sdc:value></sdc:q_HOSTNI3><sdc:q_HOSTNI4><sdc:value>0.00000</sdc:value></sdc:q_HOSTNI4><sdc:q_HOSTNI5><sdc:value>0.00000</sdc:value></sdc:q_HOSTNI5><sdc:q_HOSTNILTM><sdc:value>0.00000</sdc:value></sdc:q_HOSTNILTM><sdc:q_HOSTPTINC1><sdc:value>0.00000</sdc:value></sdc:q_HOSTPTINC1><sdc:q_HOSTPTINC2><sdc:value>0.00000</sdc:value></sdc:q_HOSTPTINC2><sdc:q_HOSTPTINC3><sdc:value>0.00000</sdc:value></sdc:q_HOSTPTINC3><sdc:q_HOSTPTINC4><sdc:value>0.00000</sdc:value></sdc:q_HOSTPTINC4><sdc:q_HOSTPTINC5><sdc:value>0.00000</sdc:value></sdc:q_HOSTPTINC5><sdc:q_HOSTPTINCLTM><sdc:value>0.00000</sdc:value></sdc:q_HOSTPTINCLTM><sdc:q_HOSTSALES1><sdc:value>0.00000</sdc:value></sdc:q_HOSTSALES1><sdc:q_HOSTSALES2><sdc:value>0.00000</sdc:value></sdc:q_HOSTSALES2><sdc:q_HOSTSALES3><sdc:value>0.00000</sdc:value></sdc:q_HOSTSALES3><sdc:q_HOSTSALES4><sdc:value>0.00000</sdc:value></sdc:q_HOSTSALES4><sdc:q_HOSTSALES5><sdc:value>0.00000</sdc:value></sdc:q_HOSTSALES5><sdc:q_HOSTSALESLTM><sdc:value>0.00000</sdc:value></sdc:q_HOSTSALESLTM><sdc:q_HOSTTASS><sdc:value>0.00000</sdc:value></sdc:q_HOSTTASS><sdc:q_HOSTTASS1><sdc:value>0.00000</sdc:value></sdc:q_HOSTTASS1><sdc:q_HOSTTASS2><sdc:value>0.00000</sdc:value></sdc:q_HOSTTASS2><sdc:q_HOSTTASS3><sdc:value>0.00000</sdc:value></sdc:q_HOSTTASS3><sdc:q_HOSTTASS4><sdc:value>0.00000</sdc:value></sdc:q_HOSTTASS4><sdc:q_HOSTTASS5><sdc:value>0.00000</sdc:value></sdc:q_HOSTTASS5><sdc:q_STATUS><sdc:value>Status:Completed</sdc:value></sdc:q_STATUS><sdc:r_PE><sdc:value>-999.00000</sdc:value></sdc:r_PE><sdc:r_PE_PRINT><sdc:value>np</sdc:value></sdc:r_PE_PRINT><sdc:r_PFTMARG><sdc:value>0.00000</sdc:value></sdc:r_PFTMARG><sdc:r_PRICEBOOK><sdc:value>-999.00000</sdc:value></sdc:r_PRICEBOOK><sdc:r_PRICEBOOK_PRINT><sdc:value>np</sdc:value></sdc:r_PRICEBOOK_PRINT><sdc:r_PTINC3YGR><sdc:value>0.00000</sdc:value></sdc:r_PTINC3YGR><sdc:r_PTINC5YGR><sdc:value>0.00000</sdc:value></sdc:r_PTINC5YGR><sdc:r_ROE><sdc:value>0.00000</sdc:value></sdc:r_ROE><sdc:r_SALES3YGR><sdc:value>0.00000</sdc:value></sdc:r_SALES3YGR><sdc:r_SALES5YGR><sdc:value>0.00000</sdc:value></sdc:r_SALES5YGR><sdc:r_SE><sdc:value>0.00000</sdc:value></sdc:r_SE><sdc:r_TASS3YGR><sdc:value>0.00000</sdc:value></sdc:r_TASS3YGR><sdc:r_TASS5YGR><sdc:value>0.00000</sdc:value></sdc:r_TASS5YGR><sdc:r_TTCFMULT><sdc:value>0.00000</sdc:value></sdc:r_TTCFMULT><sdc:r_TTEBITMULT><sdc:value>0.00000</sdc:value></sdc:r_TTEBITMULT><sdc:r_VALNA><sdc:value>0.00000</sdc:value></sdc:r_VALNA><sdc:sic_SIC><sdc:value sdc:p="0">2833:Medicinal chemicals and botanical products</sdc:value><sdc:value sdc:p="1">2834:Pharmaceutical preparations</sdc:value><sdc:value sdc:p="2">2836:Biological products, except diagnostic substances</sdc:value></sdc:sic_SIC><sdc:upa_UPACIDGEN><sdc:value>5310002</sdc:value></sdc:upa_UPACIDGEN><sdc:upa1_EXCHANGE><sdc:value>Tokyo 1</sdc:value></sdc:upa1_EXCHANGE><sdc:upa1_NATION><sdc:value>Japan</sdc:value></sdc:upa1_NATION><sdc:upa1_SICP><sdc:value>2834</sdc:value></sdc:upa1_SICP><sdc:upa1_STATE><sdc:value>Foreign</sdc:value></sdc:upa1_STATE><sdc:upa1_STATUS><sdc:value>Public</sdc:value></sdc:upa1_STATUS><sdc:upa1_TICKER><sdc:value>4568</sdc:value></sdc:upa1_TICKER><sdc:upsic_SIC><sdc:value sdc:p="0">2833:Medicinal chemicals and botanical products</sdc:value><sdc:value sdc:p="1">2834:Pharmaceutical preparations</sdc:value><sdc:value sdc:p="2">2836:Biological products, except diagnostic substances</sdc:value></sdc:upsic_SIC><sdc:upt_UPTCIDGEN><sdc:value>1084406001</sdc:value></sdc:upt_UPTCIDGEN><sdc:upt1_NATION><sdc:value>India</sdc:value></sdc:upt1_NATION><sdc:upt1_SICP><sdc:value>2834</sdc:value></sdc:upt1_SICP><sdc:upt1_STATE><sdc:value>Foreign</sdc:value></sdc:upt1_STATE><sdc:upt1_STATUS><sdc:value>Private</sdc:value></sdc:upt1_STATUS><sdc:x_RANK1_VALUE><sdc:value>0.00000</sdc:value></sdc:x_RANK1_VALUE><sdc:x_RANK_HOSTRANKVAL><sdc:value>0.00000</sdc:value></sdc:x_RANK_HOSTRANKVAL><sdc:x_RANK_RANKVAL><sdc:value>0.00000</sdc:value></sdc:x_RANK_RANKVAL><sdc:x_rank_rankstgval><sdc:value>0.00000</sdc:value></sdc:x_rank_rankstgval></sdc:deal><category>Deal Information</category><alacra:ip>TF Mergers &amp; Acquisitions</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/ccbn/T2187814</link><ccbn:docid xmlns:ccbn="http://www.alacra.com/ccbn">T2187814</ccbn:docid><guid isPermaLink="false">ccbn/T2187814</guid><ccbn:index_mode xmlns:ccbn="http://www.alacra.com/ccbn">norm</ccbn:index_mode><pubDate>24 Apr 2009 06:06:00 EST</pubDate><ccbn:eventid xmlns:ccbn="http://www.alacra.com/ccbn">2187814</ccbn:eventid><ccbn:headline xmlns:ccbn="http://www.alacra.com/ccbn">Final Transcript of RANBAXY earnings conference call or presentation, 24-Apr-09 6:30pm IST</ccbn:headline><ccbn:name xmlns:ccbn="http://www.alacra.com/ccbn">RANBAXY LABORATORIES LTD</ccbn:name><ccbn:price xmlns:ccbn="http://www.alacra.com/ccbn">54.0000</ccbn:price><ccbn:revision xmlns:ccbn="http://www.alacra.com/ccbn">Final</ccbn:revision><ccbn:storetitle xmlns:ccbn="http://www.alacra.com/ccbn">RANBAXY LABORATORIES LTD Q1 2009 Earnings Conference Call Transcript</ccbn:storetitle><ccbn:ticker xmlns:ccbn="http://www.alacra.com/ccbn">RANBAXY</ccbn:ticker><ccbn:time xmlns:ccbn="http://www.alacra.com/ccbn">6:30pm IST</ccbn:time><title>RANBAXY LABORATORIES LTD Q1 2009 Earnings Conference Call Transcript</title><ccbn:type xmlns:ccbn="http://www.alacra.com/ccbn">Transcript</ccbn:type><description>...Vikas Sonawale Religare Capital Markets - Analyst Malvinder Mohan Singh Ranbaxy Laboratories Ltd - Chairman, CEO &amp; Managing Director Omesh Sethi Ranbaxy Laboratories Ltd - CFO C O N F E R E N C E C A L L P A R T I C I P A N T S...

</description><category>Credit &amp; Investment Research</category><alacra:ip>Thomson StreetEvents</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/ccbn/T2076234</link><guid isPermaLink="false">ccbn/T2076234</guid><ccbn:index_mode xmlns:ccbn="http://www.alacra.com/ccbn">norm</ccbn:index_mode><ccbn:docid xmlns:ccbn="http://www.alacra.com/ccbn">T2076234</ccbn:docid><description>...Ladies and gentlemen, good evening, this is Melissa, the Chorus Call conference operator. Welcome to the Q# and FY#### earnings conference call of Ranbaxy Laboratories Limited hosted by Religare Securities Limited. As a reminder for the duration of the presentation, all participants are in the listen-only mode and this conference is being recorded. After the presentation, there will be an opportunity for you to ask questions. (Operator Instructions). At this time, I would now like to hand the proceedings to Mr. Vikas Sonewale, pharma analyst at Religare Securities Limited; thank you and over to you Mr. Vikas Sonewale. ...

</description><pubDate>22 Jan 2009 04:07:00 EST</pubDate><ccbn:name xmlns:ccbn="http://www.alacra.com/ccbn">RANBAXY LABORATORIES LTD</ccbn:name><ccbn:price xmlns:ccbn="http://www.alacra.com/ccbn">54.0000</ccbn:price><ccbn:revision xmlns:ccbn="http://www.alacra.com/ccbn">Final</ccbn:revision><ccbn:storetitle xmlns:ccbn="http://www.alacra.com/ccbn">FY 2008 RANBAXY LABORATORIES LTD Earnings Conference Call Transcript</ccbn:storetitle><ccbn:ticker xmlns:ccbn="http://www.alacra.com/ccbn">RANBAXY</ccbn:ticker><ccbn:time xmlns:ccbn="http://www.alacra.com/ccbn">5:45pm IST</ccbn:time><title>FY 2008 RANBAXY LABORATORIES LTD Earnings Conference Call Transcript</title><ccbn:type xmlns:ccbn="http://www.alacra.com/ccbn">Transcript</ccbn:type><category>Credit &amp; Investment Research</category><alacra:ip>Thomson StreetEvents</alacra:ip></item></channel></rss>